These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 16149177)

  • 1. New tests for heart disease: promise but no payoff. Three new blood tests designed to detect early heart disease aren't quite ready for prime time.
    Harv Heart Lett; 2005 Jul; 15(11):6--7. PubMed ID: 16149177
    [No Abstract]   [Full Text] [Related]  

  • 2. Inflammatory markers of coronary risk.
    Rader DJ
    N Engl J Med; 2000 Oct; 343(16):1179-82. PubMed ID: 11036126
    [No Abstract]   [Full Text] [Related]  

  • 3. FDA approves test for heart-disease marker.
    Health News; 2003 Oct; 9(10):10. PubMed ID: 14619771
    [No Abstract]   [Full Text] [Related]  

  • 4. Tests that predict your cardiac future. Several tests assess risk of coronary heart disease, heart attack and death from heart disease, but can better prediction lead to successful prevention?
    Heart Advis; 2007 Jul; 10(7):3. PubMed ID: 17695653
    [No Abstract]   [Full Text] [Related]  

  • 5. Predicting the risk of coronary heart disease. II: the role of novel molecular biomarkers and genetics in estimating risk, and the future of risk prediction.
    Dent TH
    Atherosclerosis; 2010 Dec; 213(2):352-62. PubMed ID: 20619412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group.
    Packard CJ; O'Reilly DS; Caslake MJ; McMahon AD; Ford I; Cooney J; Macphee CH; Suckling KE; Krishna M; Wilkinson FE; Rumley A; Lowe GD
    N Engl J Med; 2000 Oct; 343(16):1148-55. PubMed ID: 11036120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New test predicts heart risk.
    FDA Consum; 2003; 37(5):6. PubMed ID: 14666894
    [No Abstract]   [Full Text] [Related]  

  • 8. Predicting cardiovascular risk: so what do we do now?
    Lloyd-Jones DM; Tian L
    Arch Intern Med; 2006 Jul; 166(13):1342-4. PubMed ID: 16831997
    [No Abstract]   [Full Text] [Related]  

  • 9. Two markers complement each other in identifying risk.
    SoRelle R
    Circulation; 2004 Feb; 109(7):e9012. PubMed ID: 14981022
    [No Abstract]   [Full Text] [Related]  

  • 10. When is a new prediction marker useful? A consideration of lipoprotein-associated phospholipase A2 and C-reactive protein for stroke risk.
    Greenland P; O'Malley PG
    Arch Intern Med; 2005 Nov; 165(21):2454-6. PubMed ID: 16314539
    [No Abstract]   [Full Text] [Related]  

  • 11. Procalcitonin and brain natriuretic peptide as parameters in the postoperative course of patients with major pulmonary resection.
    Hoksch B; Fahrner R; Alexander Schmid R
    Interact Cardiovasc Thorac Surg; 2007 Apr; 6(2):155-9. PubMed ID: 17669797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New tests for heart disease.
    Johns Hopkins Med Lett Health After 50; 2005 Dec; 17(10):4-5. PubMed ID: 16435426
    [No Abstract]   [Full Text] [Related]  

  • 13. Stopping stroke before it strikes.
    Bloom S
    J Clin Invest; 2005 Aug; 115(8):1968. PubMed ID: 16075036
    [No Abstract]   [Full Text] [Related]  

  • 14. Biomarkers in stable coronary heart disease, their modulation and cardiovascular risk: The LIPID biomarker study.
    Tonkin AM; Blankenberg S; Kirby A; Zeller T; Colquhoun DM; Funke-Kaiser A; Hague W; Hunt D; Keech AC; Nestel P; Stewart R; Sullivan DR; Thompson PL; West M; White HD; Simes J;
    Int J Cardiol; 2015 Dec; 201():499-507. PubMed ID: 26318511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Markers of inflammation and their clinical significance.
    Ballantyne CM; Nambi V
    Atheroscler Suppl; 2005 May; 6(2):21-9. PubMed ID: 15823493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany.
    Koenig W; Khuseyinova N; Löwel H; Trischler G; Meisinger C
    Circulation; 2004 Oct; 110(14):1903-8. PubMed ID: 15451783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipoprotein-associated phospholipase A2 and cardiovascular risk: state of the evidence and future directions.
    Iribarren C
    Arterioscler Thromb Vasc Biol; 2006 Jan; 26(1):5-6. PubMed ID: 16373620
    [No Abstract]   [Full Text] [Related]  

  • 18. Biomarkers provide clues to earlier diagnoses. Tiny molecules in the bloodstream may help doctors identify heart disease sooner, which could lead to more timely treatments.
    Heart Advis; 2007 Sep; 10(9):7. PubMed ID: 18251066
    [No Abstract]   [Full Text] [Related]  

  • 19. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study.
    Folsom AR; Chambless LE; Ballantyne CM; Coresh J; Heiss G; Wu KK; Boerwinkle E; Mosley TH; Sorlie P; Diao G; Sharrett AR
    Arch Intern Med; 2006 Jul; 166(13):1368-73. PubMed ID: 16832001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.
    Ballantyne CM; Hoogeveen RC; Bang H; Coresh J; Folsom AR; Heiss G; Sharrett AR
    Circulation; 2004 Feb; 109(7):837-42. PubMed ID: 14757686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.